As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.
The haemoglobinopathies industry is being driven by the growing occurrence of haemoglobinopathies across the globe. Based on end use, the diagnostic laboratories are expected to account for a significant share in industry over the forecast period. The growth can be attributed to the development of advanced diagnostic facilities in different parts of the world. Moreover, the increasing initiatives by the government and private organisations to spread awareness regarding haemoglobinopathies is further aiding the industry growth. For instance, in September 2018, the National Institutes of Health launched the Cure Sickle Cell Initiative to forward the development of cures for sickle cell disease, which has significantly contributed to the market growth. This initiative will take support of the latest genetic discoveries and technological advances to move forward and discover the most promising genetic-based curative therapies safely into clinical trials in the coming years. Some of the key players in the industry include Bluebird Bio, Inc. (NASDAQ: BLUE) and Global Blood Therapeutics, Inc. (NASDAQ: GBT).
According to estimates, there are over 100,000 people age 12 years and older in the Gulf Cooperation Council (GCC) region, living with sickle cell disease (SCD). In September 2020, Global Blood Therapeutics, Inc. announced that the company has entered into an agreement with Biopharma-Middle East and Africa (Biopharma-MEA) to distribute Oxbryta® (voxelotor) tablets in six middle eastern countries, namely, Bahrain, Kuwait, Oman, Saudi Arabia, Qatar, and the United Arab Emirates, which collectively form the GCC region. In November 2019, Oxbryta, which is an oral, once-daily therapy for people suffering from sickle cell disease, received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of SCD in adults and children 12 years of age and older. Such developments are expected to drive the haemoglobinopathies industry growth over the forecast period.
Market Breakup by Type, Test Type, End Use, and Region:
Key Findings of the Report:
Key Offerings of the Report:
The major players in the global haemoglobinopathies market are Sanofi, Bluebird Bio, Inc., Emmaus Medical, Inc., Prolong Pharmaceuticals, LLC., and Global Blood Therapeutics, Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.